Industry News · Industry News archive
Industry News — October 2026
2026-10-23 2 articles
Isomorphic Labs' reported valuation raises the stakes for AI drug discovery
- STAT's AI Prognosis column asks what Isomorphic Labs' very high valuation says about AI's role in drug development.
- Separate reports describe early talks to raise new funds at a valuation of at least $40 billion, shortly after a roughly $2.1 billion round in May 2026; no financing has closed.
- The column also touches on the debate over AI and the cost of care.
A valuation at this level prices in platform optionality, not pipeline: Isomorphic has no disclosed clinical-stage proof yet, so investors are paying for the possibility that structure-prediction AI compresses the road to a first candidate. For the rest of the sector, it raises the bar for what AI-native biotechs must show clinically, and it will pull partnering money toward the leaders. Treat the figure as talks, not a closed deal.
Lilly bets on Metis's AI platform for tissue-targeted lipid nanoparticles
- Eli Lilly and Hong Kong-listed METiS TechBio agreed a collaboration worth up to about $1.1 billion to develop tissue-specific delivery technologies.
- METiS contributes its AiLNP platform for ionizable lipid discovery, combining a large lipid library, screening and a lipid language model.
- Metis gets a low double-digit-million upfront, plus development, regulatory and commercial milestones and single-digit tiered royalties; no candidates or indications were named.
The headline figure is almost all contingent, so the real signal is the low-eight-figure upfront: Lilly is buying an option on delivery chemistry, not an asset. Extra-hepatic LNP targeting is the bottleneck for genetic medicines, and Lilly keeps stacking deals around it. For competitors in LNP design, the question is whether AI-generated lipid libraries can show reproducible tissue selectivity in vivo.
Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery ↗
2026-10-22 3 articles
GSK wins FDA approval for its hepatitis B drug
- STAT reports that GSK has won FDA approval for its hepatitis B drug.
- The drug extended functional cures to far more patients than previous methods, according to the report.
- Details beyond the headline were not available to us; the product is understood to be the antisense bepirovirsen.
A functional-cure label in hepatitis B is a landmark for the field, and GSK gets it with an antisense oligo, not a small molecule or antibody. The commercial question is uptake: finite treatment courses mean less recurring revenue per patient, but a large, long-diagnosed population. Watch Vir, Arbutus and the Chinese siRNA players, who now have a bar to clear.
Roivant reports positive trial results in non-infectious uveitis
- STAT reports that Roivant announced positive trial results for its immune drug in non-infectious uveitis.
- The result could open a new market for the drug beyond its current indications.
- Only the headline and lede were available to us; the specific endpoints and data are not confirmed here.
Uveitis is a small but sticky indication where a non-steroid oral option is valued, and another label extension spreads development cost across more indications. The market will want to see the effect size against the standard of care, not just the win itself. I'd expect this to feed straight into Roivant's partnering and financing narrative for the asset.
STAT+: Roivant says closely watched immune drug succeeded in new eye disease ↗
Roche and Hansoh sign a second, much larger ADC collaboration
- Roche and China's Hansoh signed a collaboration on a portfolio of early-stage antibody-drug conjugates, its second ADC deal after a 2025 CDH17 ADC license.
- Reports put the upfront at about $400 million plus a further $110 million after a year, with total potential payments above $15 billion and royalties.
- Hansoh leads early development through global phase 1a, after which Roche takes over development outside Greater China.
The structure is the story: a platform-style deal where the licensor runs the work through phase 1a looks like Roche buying options on China's early ADC output rather than a single asset. A headline above $15 billion is mostly back-end milestones, so the real signal is a near-$500 million near-term cash commitment. It also keeps Roche in the race with Merck, Pfizer and AstraZeneca for Chinese ADC supply.
Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact ↗
2026-10-21 1 article
China proposes curbs on foreign acquisitions of critical biopharma technologies
- China is proposing new restrictions on foreign acquisitions of critical biopharma technologies as it seeks to keep control of its fast-growing drug development industry.
- Trade coverage of the draft (Fierce) describes it as targeting full transfers of proprietary cell and gene therapy, siRNA and pathogen gain-of-function platforms, while standard out-licensing and CRO/CDMO outsourcing appear to be exempt.
- The final text and timing are not confirmed.
If licensing really stays exempt, the draft mostly shuts the door on buying a Chinese platform company outright while leaving the license-in model that Western pharma has leaned on intact. That nudges deal structure toward options and NewCo licensing, not away from China. Buyers of cell, gene and siRNA platforms are the ones who should re-run their pipelines of targets.
STAT+: China moves to restrict foreign biotech acquisitions ↗
2026-10-20 2 articles
Gilead's oral emvistegrast meets the primary endpoint in Phase 2 ulcerative colitis
- Gilead's once-daily oral α4β7 integrin inhibitor emvistegrast (GS-1427) met its primary endpoint in the Phase 2 SWIFT study in ulcerative colitis.
- At the 200 mg dose, clinical remission at week 12 was roughly three times the placebo rate, with nominal significance and good tolerability.
- STAT's report is paywalled; figures here follow Gilead's own statement.
An oral α4β7 blocker is the obvious answer to injectable vedolizumab, and a roughly 23-point placebo-adjusted remission is credible for a Phase 2. But the p-values are nominal and the arms are small, so Phase 3 and Takeda's entrenched biologic franchise, not this readout, decide whether the oral convenience story pays.
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds ↗
Merck KGaA buys Silence Therapeutics for about $1.3B after siRNA Phase 2 win
- Merck KGaA will acquire Silence in an all-cash deal at $20 per ADS, an equity value of about $1.3 billion, via a UK scheme of arrangement.
- The price is a 130% premium to the prior close, and Silence called it the outcome of a competitive sale process.
- The deal follows positive Phase 2 data for Silence's siRNA divesiran in polycythemia vera.
A 130% premium for a single mid-stage asset says Merck KGaA is paying for de-risked rare-haematology data and a validated platform, not for breadth. It needs growth after its portfolio gaps, and siRNA offers a modality it can slot in. Watch whether Silence's platform survives as a standalone engine or just feeds divesiran.
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win ↗
2026-10-19 1 article
Lilly roughly doubles its Gate Bioscience Sec61 pact, to up to $870M
- Lilly expanded its collaboration with Gate Bioscience to a potential value of up to $870M, from the original 2025 pact worth up to $856M.
- The expansion adds one target, with an option on a second; Gate gets an upfront payment, further payment if a second target is chosen, research funding and milestones.
- Gate's platform works on Sec61, the channel through which secreted and membrane proteins exit the cell; targets and indications are undisclosed.
An expansion rather than a new deal is the real signal: Lilly saw enough from the first target to pay for another. With Pfizer following into Sec61 with Enodia a week later, a small-molecule channel-modulation approach to 'undruggable' secreted proteins is turning into a crowded field. Undisclosed upfront and targets make the economics hard to judge.
Gate CEO sees expanded $870M Lilly pact as 'vote of confidence' ↗
2026-10-18 1 article
Lakefront offloads its shelved CAR-T pipeline to Stoffels-backed Armed Cell
- Lakefront Biotherapeutics, the former Galapagos, is selling its abandoned cell therapy programs to Armed Cell Therapeutics, a new Belgian company co-founded and chaired by ex-Galapagos CEO Paul Stoffels.
- Reported terms are a small upfront payment (single-digit millions of euros) plus up to roughly $230 million in milestones.
- The package covers two armed CAR-Ts nearing the clinic in non-Hodgkin lymphoma and small cell lung cancer, plus three early preclinical projects.
A tiny upfront against a long milestone tail is what a buyer pays for preclinical assets nobody else wanted: the risk stays with Armed Cell, and Lakefront gets optionality without cost. For Lakefront, the signal is a clean pivot to autoimmune T-cell engagers. The open question is whether Armed Cell, run by the man who started the CAR-T bet, can fund the clinic.
Rebranded Galapagos finally finds buyer for unwanted cell therapy pipeline ↗
2026-10-17 3 articles
European regulators recommend Revolution Medicines' Rasonque for pancreatic cancer
- Following FDA approval, European regulators have recommended approval of Revolution Medicines' Rasonque (daraxonrasib) for pancreatic cancer, per STAT+.
- The recommendation moves the RAS(ON) inhibitor toward a second major market.
- This summary rests on the article's teaser; a separate search could not confirm the EU opinion.
If confirmed, a quick EU follow-on after the US nod shows how fast an oral RAS(ON) inhibitor with a clear survival benefit in a deadly cancer can move. For analysts the questions now shift to pricing, reimbursement and label expansion beyond second-line pancreatic disease. It also validates the tri-complex approach for peers still chasing KRAS in the same tumor type.
STAT+: RevMed's pancreatic cancer drug nears European approval ↗
AstraZeneca pays insitro $40M upfront for AI-driven liver and heart target discovery
- AstraZeneca and insitro signed a collaboration to find novel drug targets for liver and heart diseases using AI.
- Reported terms: a modest upfront payment of $40 million, with milestones taking the total to about $1.5 billion.
- Terms come from search-snippet reporting of the Fierce Biotech article, which could not be opened directly.
A small upfront against a large biobucks headline is the standard shape for platform-style target discovery: AstraZeneca pays for optionality, not assets. The partner choice shows where AZ sees the pharmacology bottleneck, in picking targets rather than designing molecules. I'd read it as another hedge alongside its other AI deals; the payoff comes only if the targets are credible.
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs ↗
Merck and Moderna say their mRNA cancer vaccine plan still needs a lot of exploring
- At the STAT Summit, Moderna's Stephen Hoge and Merck's Dean Li discussed pairing Keytruda with personalized mRNA cancer vaccines.
- Both executives framed the first positive results as a start, with much left to work out.
- This summary rests on the article's teaser, not the full text.
Pairing a personalized vaccine with Keytruda protects Merck's franchise as PD-1 exclusivity ages, so Merck has a strategic reason beyond the science. The executives' caution about what comes next is telling: the open questions are tumor types, dosing settings and manufacturing scale. Rivals with other neoantigen approaches should read it as a bar to clear.
Merck and Moderna have 'lot of exploring to do' after initial cancer vaccine success ↗
2026-10-16 5 articles
Verastem reports encouraging early data for its oral KRAS G12D inhibitor in pancreatic cancer
- Verastem presented early results for its KRAS G12D inhibitor, studied in more than 200 patients with advanced solid tumors including metastatic pancreatic cancer and others.
- Other coverage describes anti-tumor activity and a manageable safety profile across pancreatic, colorectal and lung cancers.
- This summary rests on the public lead of a paywalled STAT piece plus secondary reports, so details are limited.
KRAS G12D in pancreatic cancer is the biggest open space after G12C, and early activity with clean liver safety is what the field needs to see. The competitive question is durability against other G12D programs, including those from large players. Registration-directed Phase 2 trials and Fast Track status give Verastem a credible path, but single-arm early data can flatter.
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer ↗
Gilead licenses three dual-masked T-cell engagers from Vir in a deal worth up to about $1.9B
- Vir will discover, design and optimize three T-cell engagers against solid-tumor antigens on its dual-masked PRO-XTEN platform; Gilead holds exclusive rights to nominate candidates and then develops and commercializes them.
- Vir receives $90M up front ($65M cash plus a $25M equity investment) and $45M in near-term preclinical milestones.
- Up to $1.74B in development, regulatory and commercial milestones and tiered royalties could follow.
This is Gilead's third T-cell engager move in a short stretch (Merus, Ouro, now Vir), so the oncology thesis is clearly masked, conditional-activation TCEs for solid tumors. For Vir, it's the second platform deal this year and non-dilutive cash that lets it fund its own pipeline; the equity premium shows Gilead's commitment. Preclinical risk stays high.
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs ↗
Zealand pays $30M upfront for Generate's AI-designed multispecific proteins in obesity
- Generate will use its AI platform to design multispecific proteins for obesity and metabolic disease, leading research to lead-candidate selection.
- Zealand then takes over clinical development, regulatory work and commercialization, starting with two programs and an option on a third.
- Reported terms: $30M upfront, up to $35M of early preclinical milestones and nearly $1.2B in total milestones plus tiered royalties.
Zealand already has Roche and Boehringer on its obesity assets, and this adds a third modality bet, AI-designed biologics, with a small upfront. The structure keeps risk on Generate until a lead exists. For Generate, it's another big-pharma-style validation after Novartis and Amgen, although multispecifics in obesity are still unproven clinically.
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline ↗
Pfizer partners with Enodia on Sec61 inhibitors in a deal worth over $500M
- Enodia will use its platform to find and develop Sec61 inhibitors against several targets; Pfizer takes on clinical, manufacturing, regulatory and commercial work.
- The upfront is undisclosed; R&D and sales milestones could push the total above $500M, with tiered royalties on top.
- It follows Lilly's deal with Gate Bioscience in the same Sec61 space, reportedly worth about $870M.
Sec61 is a hard target: it is a core translocon, and the chemistry has to block only disease-linked proteins without general toxicity. Two big pharmas moving within a week suggests selectivity data are persuasive behind closed doors, but the undisclosed upfront and targets mean the real signal is still thin. Watch which client proteins each company is going after.
Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field ↗
Roche licenses Rona's ALK7-targeting RNAi obesity candidate in a deal worth up to $1.16B
- Roche gets an exclusive license to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity.
- Terms: up to $100M in upfront and near-term milestones, plus up to $1.06B in longer-term milestones and tiered royalties.
- The program's codename and development stage were not disclosed.
ALK7 is the second hot RNAi obesity target after GSK's earlier SiranBio deal, and Roche says it wants to be a top-three obesity player, so this is portfolio-building on the cheap: small upfront, back-loaded milestones. It's also Roche's fifth deal with a Chinese drugmaker since late August, a sign that the best-priced early assets are still found there.
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race ↗
2026-10-15 1 article
Sanofi settles EU antitrust probe over disparaging a rival flu vaccine, no fine
- EU antitrust regulators accepted concessions from Sanofi to close a probe into an allegedly misleading campaign that disparaged a rival flu vaccine.
- Because the case ended on accepted commitments, Sanofi avoids a fine.
- Details of the commitments are behind STAT's paywall; this summary rests on the public excerpt only.
A commitments decision is the cheap exit: no infringement finding, no fine, and little disruption to the flu franchise's commercial playbook. The wider signal is that regulators are watching comparative vaccine messaging, so rivals' medical-affairs and marketing teams will likely be more careful about how they position products against competitors.
2026-10-14 1 article
Patient advocates press safety concerns over Neurocrine's Prader-Willi drug Vykat XR
- STAT reports growing alarm among patient advocates and some experts over the perceived risks of Neurocrine's rare disease drug Vykat XR (diazoxide choline) for Prader-Willi syndrome.
- Earlier coverage links the concern to fluid retention, respiratory and cardiac events in post-marketing reports, though causality has not been established.
- Neurocrine has said it keeps a favourable benefit-risk view and is working with the FDA and patient groups.
This is a launch-curve story. Neurocrine paid heavily for Vykat XR as a blockbuster hopeful, and prescriber caution in a small, fragile patient population can slow uptake long before any regulatory action. The key variables are whether the label changes and whether the planned 2027 study in higher-risk patients reassures.
STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug ↗
2026-10-12 2 articles
Life Biosciences reports three glaucoma patients dosed with reprogramming therapy
- Life Biosciences said three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug.
- No serious adverse events were reported so far.
- Only the public lede was readable, so dose, follow-up length and efficacy readouts are unverified here.
Three patients with no serious events is a safety whisper, not a signal, but epigenetic reprogramming in humans is so new that every clean cohort moves the field's risk perception. The meaningful tests are duration of follow-up and any visual-function readout; until then this is a platform story, not a pipeline one.
STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug ↗
Viatris to buy Pacira for about $1.65B to add non-opioid pain franchise
- Viatris agreed to acquire Pacira BioSciences in an all-cash deal at $36.50 per share, a premium of roughly 45% to the last close.
- The prize is Pacira's non-opioid products EXPAREL for post-surgical pain and ZILRETTA for knee osteoarthritis pain, plus a knee OA gene therapy candidate.
- Closing is expected by the end of 2026, funded mainly from cash on hand.
This is Viatris buying a commercial pain franchise rather than science, which fits its pivot from generics toward branded cash flow. The pairing with its pending fast-acting meloxicam decision hints at a non-opioid pain sales force, though EXPAREL's generic-style competition is the long-term risk to watch.
Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B ↗
2026-10-10 2 articles
Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's study
- STAT reports that argenx said its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial in patients with Sjögren's disease, a chronic autoimmune disorder.
- STAT frames it as an unusual setback for a franchise that has mostly succeeded in label expansion; detailed data were not visible in the public lede.
Sjögren's was pitched as one of the larger expansion opportunities, so this trims the long-term sales ceiling without touching the core neuromuscular franchise. It also muddies the read-across for other Sjögren's programs: if FcRn blockade alone is not enough, bets on mechanisms that hit the disease upstream, such as Amgen's dazodalibep, look relatively better.
STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease ↗
ArriVent's first-line EGFR exon 20 NSCLC phase 3 misses its primary endpoint
- Fierce Biotech reports that ArriVent's phase 3 FURVENT trial of the EGFR inhibitor firmonertinib missed its primary progression-free survival endpoint by blinded central review in first-line EGFR exon 20 insertion NSCLC.
- The higher dose showed only a modest numerical edge over platinum chemotherapy and the lower dose did numerically worse, while investigator-assessed results looked more favorable.
- ArriVent's shares fell sharply on the news.
A small central-review margin over chemo, in a setting where J&J's Rybrevant-plus-chemo regimen has already set a higher bar, leaves firmonertinib hard to position in exon 20. The investigator-versus-central gap gives ArriVent a regulatory conversation but a thin commercial story. The PACC-mutation ALPACCA study now looks like the company's real value driver.
2026-10-09 3 articles
Roche signs molecular glue discovery deal with China's Defand Therapeutics
- STAT reports Roche has signed a drug discovery deal with Chinese biotech Defand Therapeutics focused on molecular glue medicines.
- Only the public lede of the STAT+ article could be read, so financial terms and targets are unverified here.
Roche keeps adding molecular glue partners rather than betting on one platform, and sourcing from Chinese biotechs fits the wider licensing trend. Without upfront and milestone figures I'd treat this as a discovery-stage option play, with the real signal being which targets and how many are named.
STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines ↗
Forbion closes $2.6B, its largest fundraise and among Europe's biggest in years
- STAT reports European venture firm Forbion has raised $2.6 billion, its largest fundraise to date.
- It is described as one of the largest in the region in recent years; fund structure and allocation were not visible in the public lede.
A raise this size from a specialist investor says LPs still back biotech formation despite a choppy funding climate, and it gives European startups a deeper home-market option. The things to watch are the split between early-stage company creation and later rounds, and whether it pulls US-bound founders toward European listings.
STAT+: Forbion raises $2.6 billion, its largest fundraise to date ↗
Dutch court halts Merck's subcutaneous Keytruda in several European countries
- STAT reports a Dutch court ordered Merck to stop manufacturing and marketing its subcutaneous Keytruda formulation in several European countries.
- Only the public lede was readable, so the plaintiff, grounds and scope are unverified here.
Subcutaneous Keytruda is Merck's main defense against the coming pembrolizumab biosimilar era, so any European delay hits that lifecycle plan directly. How long the order lasts and whether it is overturned on appeal matters more than the headline, and the case echoes the broader fight over SC hyaluronidase formulation patents.
STAT+: Merck suffers a setback in Europe over its new Keytruda formulation ↗
2026-10-08 2 articles
Caribou Biosciences winds down after failing to fund late-stage CAR-T trial
- STAT reports the Doudna co-founded company is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma.
- Other coverage describes the company stopping development of its two clinical cell therapy candidates and cutting most staff while exploring a merger or sale.
- Only the public STAT+ summary was available, so details beyond that are unverified.
A flagship CRISPR-era CAR-T name folding over a funding gap says the off-the-shelf cell therapy thesis is struggling to raise money against autologous products and bispecifics. It reads more as a financing failure than a clean scientific verdict, so watch whether the assets and data find a buyer.
STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down ↗
AstraZeneca opens $1B Kendall Square R&D site amid China dealmaking wave
- AstraZeneca opened a new R&D site in Boston's Kendall Square, marking a $1 billion investment.
- STAT frames the opening against a backdrop of heavy dealmaking with Chinese biotechs and uncertainty in the US biotech hub.
- Only the public STAT+ summary was available; site scope and headcount are not verified.
Planting a $1B flag in Kendall Square while licensing heavily from China looks like hedging: keep US discovery talent close even as external innovation shifts east. It's a capex signal, not a pipeline one, so the tell is whether the site hosts internal discovery or mostly integrates in-licensed assets.
2026-10-07 3 articles
Lycia files for a $100M IPO to take its LYTAC degraders into allergy
- Lycia Therapeutics filed publicly for an IPO of up to $100M on Nasdaq under LYCA, after a confidential filing in July.
- Its LYTAC platform, from Carolyn Bertozzi's lab, shuttles extracellular proteins to the lysosome for degradation.
- Lead LCA-0061 degrades IgE for food allergy and is in Phase 1; LCA-0321 targets Graves' disease autoantibodies.
Early healthy-volunteer data showing a deep IgE drop give the story a clinical anchor, and an IPO is a useful test of public-market appetite for degraders outside oncology. The competition is formidable, though: omalizumab and its successors already own IgE, so Lycia must show a durable, differentiated edge.
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms ↗
Genentech pays Alector $100M upfront for brain-penetrant GCase therapy AL050
- Alector licensed AL050, a preclinical brain-penetrant engineered GCase enzyme replacement therapy for Parkinson's disease, to Genentech.
- The deal brings $100M upfront, up to $1.17B in milestones and tiered royalties; Genentech takes development, manufacturing and commercialization.
- Alector keeps its Brain Carrier platform, and the cash extends its runway into 2029.
A $100M upfront for a preclinical asset shows how much Roche values a validated blood-brain barrier shuttle in GBA1-linked Parkinson's. For Alector, it's a lifeline that funds its Alzheimer's and siRNA programs. The risk is that delivery, not the enzyme, is the real bet, and Genentech has other shuttle options.
Genentech pays Alector $100M for preclinical Parkinson's prospect ↗
Merck pays $400M upfront for SciBrunch's preclinical KRAS G12D inhibitor
- Merck took exclusive worldwide rights to SPR2015, an oral preclinical KRAS G12D (ON) inhibitor from Shanghai-based SciBrunch.
- SciBrunch gets $400M upfront, with total potential value of $2.13B across milestones.
- The deal has already closed.
$400M upfront for a preclinical asset is striking and shows how heated the KRAS G12D race has become, with China-originated assets now priced like clinical ones. For Merck it's a late entry into a field where it needs a differentiated ON-state profile, and the one to watch is first-in-human data.
2026-10-06 4 articles
CSL pays $355M upfront to co-develop Alentis' anti-Claudin-1 antibody lixudebart
- CSL will pay $355 million upfront, plus up to $1.2 billion in commercial milestones, to co-develop and co-commercialize the anti-Claudin-1 antibody lixudebart.
- Profits split 55% CSL and 45% Alentis; CSL funds the ongoing phase 2 in ANCA-associated vasculitis with rapidly progressive glomerulonephritis and a phase 3.
- Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis are also planned.
A 55/45 profit split with a $355M upfront is unusually rich for a phase 2 asset, and it tells me CSL wants a nephrology franchise on real terms. Alentis keeps a meaningful economic stake instead of a royalty. The multi-indication plan across kidney and liver is the bet: one Claudin-1 mechanism, several fibrotic diseases.
CSL pays $355M to co-develop Alentis' phase 2-stage fibrosis drug ↗
Genmab's Rina-S posts durable phase 2 responses in platinum-resistant ovarian cancer
- Genmab reported phase 2 RAINFOL-01 data for the ADC rinatabart sesutecan (Rina-S): a 45.9% confirmed response rate in 109 heavily pretreated patients.
- Median progression-free survival was 9.5 months; TD Cowen analysts called that clearly better than the 5.6 months cited for AbbVie's Elahere.
- Activity was reported regardless of prior Elahere treatment and in patients with low or no FRα expression.
Cross-trial comparisons flatter whoever runs the later study, so I'd discount the 'clearly superior' framing. Still, activity in low-FRα and post-Elahere patients is the more interesting claim: it widens the addressable population beyond Elahere's high-expressor label. It also supports the case for the ProfoundBio buy.
Genmab's latest phase 2 data spur claim ADC is 'clearly superior' to AbbVie's Elahere ↗
FDA approves Lilly's Jaypirca for previously untreated CLL and SLL
- The FDA approved Jaypirca (pirtobrutinib) for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
- It moves the non-covalent BTK inhibitor from later-line use into the first-line setting.
First-line is where the BTK market's volume sits, so this is the label that matters commercially. It puts a non-covalent inhibitor directly against the covalent incumbents, where it competes on tolerability and on not depending on the Cys481 bond. Watch how payers and guidelines place it relative to fixed-duration venetoclax regimens.
Shionogi to buy IntraBio for $2B, adding the rare disease drug Aqneursa
- Shionogi will acquire Austin-based IntraBio for $2 billion in cash, making it a subsidiary of its US arm.
- The prize is Aqneursa, an oral therapy approved for Niemann-Pick disease type C and, since, for ataxia-telangiectasia.
- Closing is expected in November–December 2026.
Buying a commercial-stage asset outright is a shift for Shionogi, which has leaned on its anti-infective franchise and partnerships. A rare neurology product with two indications adds revenue with a modest sales force and a clear niche. The question is whether Aqneursa can grow past NPC and A-T.
Shionogi to pay $2B for IntraBio, a commercial rare disease biotech ↗
2026-10-05 2 articles
JCR grants Italfarmaco US, EU and Latin America rights to Hunter syndrome drug JR-141
- JCR Pharmaceuticals signed an exclusive license with Italfarmaco for JR-141 (pabinafusp alfa; Izcargo in Japan) in the US, Europe and Latin America.
- The blood-brain-barrier-penetrating enzyme replacement therapy targets Hunter syndrome (MPS II); it was launched in Japan in 2021 and is in Phase 3.
- Italfarmaco will commercialize after approvals; JCR keeps manufacturing and receives upfront, milestone, royalty and supply revenue. Amounts were not disclosed.
Undisclosed economics make this a structure story, not a price story. JCR hands Italfarmaco commercialization in the US, Europe and Latin America but keeps manufacturing and supply revenue, which preserves margin on a complex biologic. For Italfarmaco it is a rare-disease pipeline add; what I would want to see is Phase 3 data and regulatory timelines before judging value.
第一三共「ダトロウェイ」併用療法開発で米サミットと提携／JCRファーマ「イズカーゴ」欧米販売でライセンス契約 など｜製薬業界きょうのニュースまとめ読み（2026年10月2日） ↗
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone ↗
2026-10-04 2 articles
Survodutide's second underwhelming phase 3 read-out knocks Zealand's shares
- Boehringer Ingelheim and Zealand's survodutide produced weight loss of up to roughly 13% in people with diabetes in phase 3.
- Zealand's shares fell sharply after the data, which landed a day after Lilly's eloralintide–tirzepatide combination read-out.
- Gastrointestinal side effects drove about 18% of treated patients to stop, keeping tolerability in question.
- It is the second recent disappointment for the compound after earlier SYNCHRONIZE-1 data.
The efficacy sits between semaglutide 2.4 mg and top-dose tirzepatide, but timing is brutal: Lilly's amylin combination landed 24 hours earlier at a far higher weight-loss level. With roughly one in five patients dropping out on GI effects, survodutide's remaining angle is MASH, where glucagon activity is the differentiator, not raw weight loss. Expect investors to price Zealand on that liver story and on how Boehringer positions dosing and titration.
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 ↗
Novo bets up to $1.4B on Orbis's oral macrocycle platform
- Orbis Medicines signed a multi-target discovery and license deal with Novo Nordisk worth up to $1.4B in upfront and milestone payments plus tiered royalties.
- Novo also takes a strategic equity stake in the private Copenhagen company; this is Orbis's first pharma partnership.
- The work uses Orbis's AI-enabled nGen platform to make macrocycles aimed at turning injectable cardiometabolic therapies into orals.
- Orbis reported preclinical oral bioavailability up to 18%; targets and disease areas beyond cardiometabolic were not disclosed.
This is Novo hedging its oral strategy beyond small-molecule GLP-1s and oral semaglutide: macrocycles are the bet that peptide-like potency can survive the gut. The headline number is mostly milestones, so the real signal is the equity stake and a multi-target structure that lets Novo test the platform cheaply. Lilly is also an Orbis backer, which tells you both obesity leaders want the same oral-peptide option.
Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo ↗
2026-10-03 1 article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease
- Novartis gains worldwide exclusive rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager produced in vivo to reset B cells in autoimmune disease.
- The package is $575M upfront plus up to $7.2B in milestones (up to $7.8B in total) and royalties.
- Novartis also receives options on other Abogen RNA-based programs.
- The deal follows Novartis pausing an autoimmune CAR-T program after three deaths.
The $7.8B headline is mostly contingent; the $575M upfront is the real conviction signal. Landing this after pausing an autoimmune CAR-T program reads like Novartis hedging its B-cell reset thesis toward an in vivo, mRNA-delivered CD19xCD3 format. The options on other Abogen RNA programs suggest it is buying platform access, not just one asset.
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager ↗
2026-10-02 2 articles
Sanofi Pays Regeneron $1B Upfront to Add Four Long-Acting Immunology Antibodies to the Dupixent Alliance
- Sanofi and Regeneron expanded their alliance with $1 billion upfront and up to $7 billion in development, regulatory and commercial milestones.
- The deal adds four antibodies: clinical-stage long-acting IL-13 REGN20423, a long-acting IL-4xIL-13 bispecific and two preclinical long-acting antibodies against IL-4 pathway targets.
- Regeneron leads R&D, Sanofi leads global commercialization, and costs and profits split 50:50.
This is Sanofi buying a Dupixent successor from the one partner that already knows how to make that franchise work, ahead of the 2031 US patent expiry. Paying $1B for a Phase 1 antibody and three preclinical ones is really a bet on long-acting dosing as the differentiator against a crowded type 2 inflammation field. For Regeneron it is non-dilutive funding plus a reconfirmed partner; I'd watch whether Sanofi's other immunology assets get de-prioritized.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D ↗
Lilly's Amylin–Zepbound Combo Posts Record Weight Loss in Phase 2b, but Dropouts Rise
- EloraTZP combines the amylin agonist eloralintide with tirzepatide; in adults with obesity and type 2 diabetes it beat tirzepatide alone on weight loss and A1C at 48 weeks, with up to 23.3% weight loss at the top dose.
- Discontinuations due to adverse events were higher in the combination arms, mostly GI-related during dose escalation, which raises tolerability questions.
- Lilly plans to start phase 3 in the fourth quarter of 2026.
Beating retatrutide's diabetes-population number with an amylin add-on strengthens Lilly's case that obesity's next act is combinations, ahead of AbbVie and Pfizer amylin plays. The dropout rate is the real commercial variable: if titration cannot tame GI effects, a headline efficacy edge shrinks in practice. Phase 3 design, especially the dose-escalation schedule, will tell us how much of this is deliverable.
2026-10-01 4 articles
Novo Pays $300M Upfront for Hengrui's Weekly Oral GLP-1/GIP Agonist
- Novo gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist, for $300M upfront and up to $2.3B in milestones plus royalties.
- The asset is Phase 1-ready, with Chinese clearance to start trials in weight management and type 2 diabetes; closing is expected in Q4 2026.
Paying $300M upfront for a molecule that hasn't dosed a human outside China shows how badly Novo wants an oral follow-on while Lilly presses its lead. It also fits a pattern of buying de-risked-enough optionality from outside rather than building it, after smaller deals like Nanexa. Weekly oral bioavailability is the real technical risk, and the milestone-heavy structure shields Novo if it fails.
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug ↗
AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs
- AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
- The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.
AstraZeneca scales Summit's PD-1xVEGF strategy with $2B investment to fuel ADC combinations ↗
Merck Pulls Recarbrio From the U.S. Market, Leaving No Late-Stage Antibacterial Programs
- Merck is discontinuing Recarbrio, its reserve-use antibiotic combination, in the U.S. as part of a portfolio review, and says the move is unrelated to safety or quality.
- Approved seven years ago for hospital-acquired pneumonia and complicated urinary and abdominal infections with few options, it leaves Merck with only mature antibiotics and, per trade reports, no antibacterial programs in Phase II or later.
Reserve antibiotics are meant to be used sparingly, which caps sales, and a big pharma walking away from one confirms the broken economics of anti-infective launches. Small biotechs will read this as a warning, and policymakers will cite it in the case for pull incentives. The open question is whether Merck out-licenses the product or simply sunsets it.
Merck discontinues a crucial antibiotic despite concerns over superbug resistance ↗
Roche Drops Emugrobart in Obesity After Interim Futility; Chugai Takes It Back
- Roche ended obesity development of emugrobart (GYM329), an anti-latent-myostatin sweeping antibody meant to preserve muscle alongside GLP-1 therapy, after a Phase 2 GYMINDA interim analysis made meaningful weight loss unlikely.
- Rights revert to Chugai, which is preparing to resume development in spinal muscular atrophy and is open to out-licensing; the antibody had already missed in SMA and FSHD trials in March.
This dents the muscle-preservation thesis in obesity: the pitch was that myostatin blockade adds lean-mass benefit on top of incretins, and this antibody didn't deliver. Other myostatin and activin-pathway programs will face sharper partner questions about what retained lean mass means clinically. A rights return usually signals a deprioritized asset, and a Phase 3 in SMA after an earlier SMA miss looks like a long shot.
Roche drops muscle-sparing obesity antibody after flunked interim analysis ↗